Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
KZRSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
KZR(NASDAQ:KZR) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in two upcoming investor conferences taking place in September: Event: 2025 Wells Fargo Healthcare Conference Location: Boston, MA Date/Time: Friday, September 5, 2025, at 11:00 am ET Form
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
KZRSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “We are on track with our clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis,” said Chris Kirk, PhD, CEO and co-founder of Keza
Kezar Life Sciences Q1 EPS $(2.27) Beats $(2.61) Estimate
KZRKezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate
KZRKezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use.
Kezar Life Sciences Q4 2024 GAAP EPS $(2.77) Beats $(2.88) Estimate, Cash $132M
KZRKezar Life Sciences Provides Topline Results From The PORTOLA Phase 2a Trial Evaluating Zetomipzomib For The Treatment Of Patients With Autoimmune Hepatitis
KZRKezar Life Sciences To Present Topline Results From The Portola Phase 2a Trial Evaluating Zetomipzomib For The Treatment Of Patients With Autoimmune Hepatitis On Tuesday, March 25, 2025
KZRWells Fargo Maintains Equal-Weight on Kezar Life Sciences, Lowers Price Target to $9
KZRKezar Life Sciences Received A Letter From The Listing Qualifications Staff Of The Nasdaq Notifying The Company That It Has Regained Compliance With Nasdaq Listing Rule 5550(A)(2)
KZRWells Fargo Maintains Equal-Weight on Kezar Life Sciences, Lowers Price Target to $11
KZRWells Fargo Analyst Has Questions On Kezar's Lupus Nephritis Data Readout, Stock Plunges
KZRWhy Kezar Life Sciences Shares Are Getting Hammered
KZRKezar Life Sciences Inc (NASDAQ: KZR) shares are trading lower by 38.23% at $7.61 after the company announced top-line results from its PRESIDIO Phase 2 clinical trial of Zetomipzomib.
Wells Fargo Maintains Overweight on Kezar Life Sciences, Lowers Price Target to $14
KZRKezar Life's Lead Asset Fails To Top Placebo In Muscle Inflammation Disease
KZRKezar Announces Topline Results From PRESIDIO Trial Of Zetomipzomib For The Treatment Of Dermatomyositis And Polymyositis
KZR